Retension Pharmaceuticals
Retension Pharmaceuticals develops RTN-001, a once-daily oral treatment for uncontrolled and resistant hypertension.
Retension Pharmaceuticals (Ticker: RTSN US) develops RTN-001, a once-daily oral treatment for uncontrolled and resistant hypertension. RTN-001 is the company's sole drug candidate and is being evaluated in a Phase 2b clinical trial that began in October 2025. Founded in 2023, the company was incorporated in Delaware. The company reported a net loss of approximately $12.00 million for the 12 months ended June 30, 2026.
The scheduled listing date on Nasdaq was October 9, 2026. The proposed offering comprises 3,300,000 shares at an indicative price range of $11.00–13.00 per share. At the indicative range midpoint, the base offering would represent $39.60 million in gross proceeds, excluding any unexercised over-allotment. The indicated IPO market capitalization is $95.00 million.
Leerink Partners, Guggenheim Securities, Oppenheimer & Co. and Titan Partners are joint managers for the offering.
Prepared with IPOX® AI assistance. Information may contain errors.
